Bionor Pharma ASA : notice of results for the six months ended 30 June 2015

A conference call for analysts and investors will be held on 12 August 2015 at 09:30am CEST. David H. Solomon, CEO and Jens Krøis, CFO will provide an update on the business, followed by a Q&A session.

The call can be accessed by dialing:
Denmark: +45 32 71 16 59
United Kingdom: +44 20 3427 1905
USA: +1 646 254 3388
Norway: +47 2316 2787
Sweden: +46 850 653 938
Participant code: 8020617

A presentation will be available on our website, www.bionorpharma.com, one hour prior to the call.

A webcast of the conference call will be available during and after the event via this link: http://edge.media-server.com/m/p/jpdro44o.

Further information
Jørgen F. Ravn, VP Investor Relations & Communications, +45 20 30 39 03, jfr@bionorpharma.com

About Bionor
Bionor Pharma ASA is a leading biotechnology company advancing a potential first therapeutic vaccine towards a functional cure for HIV. The company's focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor's most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Bionor's current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study.

Bionor is headquartered in Oslo, Norway, with offices in Copenhagen and New York, and is listed on the Oslo stock exchange, under the ticker BIONOR. More information about Bionor is available at www.bionorpharma.com.